Back to top
more

Sucampo Pharmaceuticals, Inc. (SCMP)

(Real Time Quote from BATS)

$18.00 USD

18.00
NA

+0.05 (0.28%)

Updated Feb 13, 2018 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4

by Zacks Equity Research

Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.

    Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down

    by Zacks Equity Research

    Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.

      Pfizer Files for Xtandi in Early Stage Prostate Cancer

      by Zacks Equity Research

      Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.

        Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat

        by Zacks Equity Research

        Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.

          Debapriya Chakraborty headshot

          Theravance's NDA for COPD Candidate Gets FDA Acceptance

          by Debapriya Chakraborty

          The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.

            Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion

            by Zacks Equity Research

            The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.

              AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up

              by Zacks Equity Research

              AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

                Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y

                by Zacks Equity Research

                Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.

                  Shire Gets FDA Nod for Cinryze Tech Transfer to New Site

                  by Zacks Equity Research

                  Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.

                    Anthera's Sollpura Strong on Positive Futility in Phase III

                    by Zacks Equity Research

                    Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.

                      Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year

                      by Zacks Equity Research

                      Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.

                        Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?

                        by Zacks Equity Research

                        Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.

                          Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018?

                          by Zacks Equity Research

                          Endo International (ENDP) lost 35% in the past year mired by controversy related to Opana ER and weaknesses in both the businesses.

                            Aradigm's Bronchiectasis Candidate Has Negative FDA Vote

                            by Zacks Equity Research

                            The FDA panel votes against the approval of Aradigm's (ARDM) Linhaliq for treatment of non-cystic fibrosis bronchiectasis. A response from the regulatory agency is expected on Jan 26, 2018.

                              Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?

                              by Zacks Equity Research

                              We look at the factors that drive the share price of Perrigo to a 52-week high.

                                Endo (ENDP) Gets Subpoena From Florida for Opioid Misuse

                                by Zacks Equity Research

                                Endo (ENDP) announced that it received a subpoena from the Florida authorities in connection with products related to opioid misuse.

                                  Why is Novo Nordisk Stock Up More Than 50% in Past Year?

                                  by Zacks Equity Research

                                  We take a look at the factors that led to the rise in Novo Nordisk's (NVO) share price in the past year.

                                    Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up

                                    by Zacks Equity Research

                                    Adamas (ADMS) shares climb on the commercial launch of Gocovri in the United States for treating dyskinesia in patients with Parkinson's disease. This is the first FDA approved drug for the ailment.

                                      Acorda's Shares Down on Disappointing Ampyra View for 2018

                                      by Zacks Equity Research

                                      Acorda (ACOR) announces preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for Q4. The company's net sales expectations are higher year over year.

                                        Novo Nordisk Confirms Bid for Ablynx But Faces Rejection

                                        by Zacks Equity Research

                                        Novo Nordisk (NVO) confirmed its revised offer made on Dec 22, to acquire Ablynx NV for $3.1 billion.

                                          Mallinckrodt (MNK) to Sell Recothrom and Preveleak to Baxter

                                          by Zacks Equity Research

                                          Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to Baxter.

                                            Emergent Starts Phase II Study on Anti-influenza Candidate

                                            by Zacks Equity Research

                                            Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.

                                              Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod

                                              by Zacks Equity Research

                                              Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.

                                                Are Options Traders Betting on a Big Move in Sucampo (SCMP) Stock?

                                                by Zacks Equity Research

                                                Investors in Sucampo (SCMP) need to pay close attention to the stock based on moves in the options market lately.

                                                  United Therapeutics (UTHR) Collaborates With Corsair Pharma

                                                  by Zacks Equity Research

                                                  United Therapeutics (UTHR) entered into an exclusive license agreement with Corsair Pharma.